Salivadirect Inc

Initiation of Saliva Direct Inc Lab Network Sustainability Plan through Federal Drug Administration FDA engagement in preparing the De Novo authorization of the SARS-CoV-2 assay, expanding assay development to include SARs-CoV-2, influenza A/B and RSV in a multiplex PCR assay, and launching mobile testing accross New Haven by partnering with 22 community organizations. The mobile testing was deployed to 123 events across Connecticut, providing 1,428 free SARS-CoV-2 tests excedding the goal of 400 tests with high engagement from uninsured and underserved communities. The key findings indicated that 74 of participants found it easy to access the van and 75 were comfortable with using the services demonstrating the effectiveness of mobile testing in overcoming barriers such as transportation, access to healthcare and showing of strong interest in expanding mobile health services to include health screenings.